Samsung Biologics Co.,Ltd.

₩1,511,000As of Sun 8 Nov 2026, 12:00 UTC
KRX:207940Healthcare
Country South Korea
PE (Fwd) •••
TSR 10Y CAGR 23.07%
Div yield —
ROE 18.53%
Biotechnology
Beta (5Y) 0.15
PE TTM 33.17
TSR TTM (1.78%)
Mkt cap ₩69.87T
ROIC 23.55%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩1.849M
22.38%
(56.72%)
Hold 5|12|7|7|2
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
21,929
22,476
21,844
24,439
41.34%
30.87%
23.51%
23.52%
Revenue₩B
7,159
7,389
7,362
7,206
(3.14%)
2.86%
(0.64%)
(0.90%)
Peers (US$51.68B)
Cap (US$)
PE
35.54B
30.85x
10.29B
76.81x
57.29B
32.08x
Capital
TTM
5Y
10Y
Leveragex
1.757
0.042
0.035
EBIT/Intx
1.232
1.117
1.019
Own earn%
102.12
(32.10)
(35.63)
Sh yield%
42.87
31.65
31.41
Owners
Insiders/Inst%
12.74
54.37
Short interest%
4.61
SBC / revenue%
0.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
10–18
$1 testx
1.4
Incr. ROIC%
87

Samsung Biologics Co.,Ltd., with its subsidiaries, manufactures, commercializes, distributes and sells biopharmaceutical products in South Korea, Europe, the United States and internationally. It offers development services, aseptic filling, lyophilization, cold chain storage and shipping, regulatory support, quality and analytical testing, and drug substance manufacturing, and develops antibody-drug conjugates and mRNA products.